B
EBS icon

Bailard’s Emergent Biosolutions EBS Stock Holding History

Bailard’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-13,600
Closed -$114K – 776
2026
Q2 		$114K Hold
13,600
– – ﹤0.01% 756
2026
Q1 		$113K Buy
+13,600
New +$141K ﹤0.01% 722

Other funds holding EBS

Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
CIM
Contravisory Investment Management Norwell, Massachusetts $552M AUM 32.44% 1-Year Est. Return

Bailard's EBS Position: Q3 2026 in Review

Bailard sold out of Emergent Biosolutions (EBS) in Q3 2026, closing a stake of 13,600 shares — an estimated $114K sold.

Bailard first reported a position in EBS in Q1 2026 and held it in 2 quarters. The position peaked at $114K in Q2 2026. 6 funds tracked by Wall St. Rank hold EBS as of Q3 2026.

  • Bailard reported no remaining Emergent Biosolutions position as of Q3 2026 after selling out during the quarter.
  • Bailard sold 13,600 Emergent Biosolutions shares in Q3 2026, an estimated $114K.
  • Bailard first reported a position in Emergent Biosolutions in Q1 2026 and held it in 2 quarters.
  • Bailard's Emergent Biosolutions position peaked at $114K in Q2 2026.
  • 6 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2026.

Based on Bailard's 13F filing for Q3 2026, filed 13 Oct 2026.